Tumor immunotherapy: inching toward the finish line.
Curiel
Tyler J
TJ
Hematology and Medical Oncology, Tulane Medical School, New Orleans, Louisiana, USA.
Curiel
David T
DT
D000951:Antigens, Neoplasm / Q000235:genetics; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008213:Lymphocyte Activation; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D017430:Prostate-Specific Antigen / Q000235:genetics; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy; D012333:RNA, Messenger / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology; D014162:Transfection
D000951:Antigens, Neoplasm; D012333:RNA, Messenger; D017430:Prostate-Specific Antigen